Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
generic:
None (26) ·
(multiple, generic dominant) (1) ·
Alfenta (1) ·
Antivert (Rx), Bonine (OTC), Dramamine Less Drowsy (OTC) (1) ·
Benadryl (oral, injectable, topical), Banophen, Sominex (sleep aid), ZzzQuil, Aler-Dryl (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Dolophine (1) ·
Duragesic (1) ·
Heroin (1) ·
Krokodil (1) ·
Nubain (1) ·
Nucynta (1) ·
O-DSMT (1) ·
Opana (1) ·
Phenergan, Promethegan (suppositories) (1) ·
Reglan, Gimoti (intranasal), Metozolv ODT (1) ·
Stablon (1) ·
Stadol (1) ·
Suboxone (1) ·
Sufenta (1) ·
Talwin (1) ·
Ultiva (1) ·
Vicodin (1) ·
Zofran, Zofran ODT (1)
None (3) ·
Active metabolite of tramadol; mu-opioid agonist (1) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Extremely potent mu-opioid receptor agonist (1) ·
Highly potent mu-opioid receptor agonist (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) ·
Monoamine releasing agent (4) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; fentanyl analogue (1) ·
Mu-opioid receptor agonist; NMDA antagonist (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Opioid receptor partial agonist/antagonist; toxic alkaloid (1) ·
Partial mu-opioid agonist; kappa antagonist (1) ·
Partial mu-opioid receptor agonist; alpha-2 agonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (6) ·
Prodrug of morphine; mu-opioid receptor agonist (1) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Selective mu-opioid receptor agonist (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
Ultra-short-acting mu-opioid agonist (1) ·
'"`UNIQ--vote-00000013-QINU`"' Anticholinergic burden (dry mouth, blurred vision, urinary retention, cognitive effects) is the principal adverse-event concern and the basis for Beers-list cautions in elderly patients'"`UNIQ--ref-00000014-QINU`"'. (1) ·
'"`UNIQ--vote-0000001D-QINU`"' Major Beers-list concern in elderly patients for cognitive and fall risks. CYP2D6 substrate. At massive overdose, also produces sodium channel blockade with cardiac toxicity'"`UNIQ--ref-0000001E-QINU`"'.
'"`UNIQ--effect-0000001F-QINU`"' (1)
None (45) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"' (1) ·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"' (1) ·
'"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1) ·
'"`UNIQ--vote-00000374-QINU`"', '"`UNIQ--vote-00000375-QINU`"', '"`UNIQ--vote-00000376-QINU`"', '"`UNIQ--vote-00000377-QINU`"' (1) ·
'"`UNIQ--vote-00000EF4-QINU`"', '"`UNIQ--vote-00000EF5-QINU`"', '"`UNIQ--vote-00000EF6-QINU`"', '"`UNIQ--vote-00000EF7-QINU`"', '"`UNIQ--vote-00000EF8-QINU`"' (1)
None (45) ·
10 mg PO/IV/IM QID, '''not to exceed 12 weeks''' (tardive dyskinesia risk); intranasal Gimoti 15 mg BID (1) ·
4-8 mg PO or IV every 8 hours as needed; 16 mg single dose preoperatively for PONV prevention (1) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated''' (1) ·
Allergy: 25-50 mg PO every 4-6 hours. Insomnia: 25-50 mg PO at bedtime. IV (acute dystonia, severe allergic reaction): 25-50 mg slow IV push (1) ·
Motion sickness: 25-50 mg PO 1 hour before travel, repeat every 24 hours as needed. Vertigo: 25-100 mg/day divided (1)
None (45) ·
4 mg, 8 mg, 24 mg tablets; 4 mg, 8 mg orally disintegrating tablets; 4 mg/5 mL oral solution; IV (2 mg/mL) (1) ·
5, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL IV; 15 mg/spray intranasal (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) ·
Tablets 12.5, 25 mg; chewable tablets 25 mg (1) ·
Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL (1) ·
Tablets 25, 50 mg; capsules; liquid; chewable; topical cream/gel; injection 50 mg/mL (1)
None (45) ·
12-15 hours'"`UNIQ--ref-00000022-QINU`"' (1) ·
2.5–3 hours (1) ·
3-6 hours (longer in hepatic impairment)'"`UNIQ--ref-00000378-QINU`"' (1) ·
4-8 hours (longer in elderly, 9-13 hours)'"`UNIQ--ref-00000026-QINU`"' (1) ·
5-6 hours'"`UNIQ--ref-00000EF9-QINU`"' (1) ·
~6 hours'"`UNIQ--ref-00000018-QINU`"' (1)
None (45) ·
~25% (oral)'"`UNIQ--ref-00000019-QINU`"' (1) ·
~25% (oral, with extensive first-pass)'"`UNIQ--ref-00000023-QINU`"' (1) ·
~40-60% (oral, with significant first-pass)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~50% (variable, CYP2D6-dependent for analgesic effect). (1) ·
~60% (oral)'"`UNIQ--ref-00000379-QINU`"' (1) ·
~80% (oral; reduced by significant first-pass)'"`UNIQ--ref-00000EFA-QINU`"' (1)
None (46) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Older agent with substantial use experience, including in hyperemesis gravidarum; broadly reassuring observational data'"`UNIQ--ref-00000024-QINU`"' (1) ·
Older agent with substantial use experience; broadly considered safe in pregnancy'"`UNIQ--ref-00000028-QINU`"' (1) ·
Older agent with substantial use experience; observational signals reassuring for first-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Widely used for hyperemesis gravidarum; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
None (46) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Over-the-counter|OTC]] as Bonine and Dramamine Less Drowsy; [[USLegal:Prescription only|Rx-only]] as Antivert (1) ·
[[USLegal:Over-the-counter|OTC]] for most oral and topical formulations; [[USLegal:Prescription only|Rx-only]] for injectable (1) ·
[[USLegal:Prescription only|Rx-only]] in US (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for '''tardive dyskinesia''' (irreversible movement disorder), driving the 12-week chronic-use limit'"`UNIQ--ref-00000EFB-QINU`"' (1)
Showing below up to 51 results in range #1 to #51.


